[Induction of immunogenic variant of a murine fibrosarcoma].
Immunogenic variant was induced from the methylcholanthrene induced fibrosarcoma (MCA-F) by in vitro treatment with the mutagen 1-methyl-3-nitro-1-nitrosoguanidine (MNNG). D-10 tumor cell which was cloned from MNNG treated MCA-F tumor cell was rejected by normal syngeneic C3H-HeJ mice but not by 650 rad irradiated immunosuppressed mice. Host which had rejected D-10 tumor growth, rejected parental MCA-F tumor cells. But active immunotherapy using D-10 tumor cell against MCA-F tumor cells. But active immunotherapy using D-10 tumor cell against MCA-F tumor bearing mice was not successful. Cytotoxic T cell (CTL) established from D-10 immunized spleen cells showed D-10 specific cytotoxic activity and not lysed parent MCA-F cells. CTL clone C-E-6 showed specific cytotoxic and proliferative activity against D-10 cell. In vivo tumor neutralizing assay also showed its specificity against D-10 tumor cell. Active immunotherapy and adoptive immunotherapy using immunogenic variant, D-10 was not successful. D-10 tumor cell possesses very strong neoantigen induced by MNNG treatment and parental MCA-F antigen.
Kobayashi
M
M
Second Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
Yamagishi
H
H
Nomi
S
S
Ueda
Y
Y
Hayashi
T
T
Oka
T
T
D000818:Animals; D000951:Antigens, Neoplasm / Q000378:metabolism; D005260:Female; D005354:Fibrosarcoma / Q000139:chemically induced / Q000276:immunology* / Q000628:therapy; D007111:Immunity, Cellular; D016233:Immunotherapy, Active; D016219:Immunotherapy, Adoptive; D008748:Methylcholanthrene; D008769:Methylnitronitrosoguanidine; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation
D000951:Antigens, Neoplasm; D008769:Methylnitronitrosoguanidine; D008748:Methylcholanthrene